DGAP-News: curasan AG: Patent granted for platelet-mediator concentrate
(firmenpresse) - DGAP-News: curasan AG / Key word(s): Miscellaneous
curasan AG: Patent granted for platelet-mediator concentrate
30.08.2012 / 08:40
---------------------------------------------------------------------
curasan AG, listed in the General Standard (ISIN: DE 000 549 453 8), can
now refer to a patent with regard to the marketing of their ATR(R)-curasan
set.
The ATR(R) (Advanced Tissue Regeneration) system is a standardized
procedure for extracting growth factors from whole blood by means of
sedimentation and filtration. This innovative technology was developed by
an expert team of medical doctors and scientists in cooperation with
curasan AG as an improvement of existing methods with which platelet rich
plasma is obtained with centrifuges.
Curasan AG has the rights of use for the patented process for selected
European markets and offers the product including its related equipment
under the name of ATR(R)-curasan set.
The platelet mediator concentrate obtained with the ATR(R)-curasan set,
ensures a high degree of compatibility as it is extracted from the
patient's own blood.
The profoundly pure platelet mediator concentrate (PMC) consists only of
active components and is free of cellular parts. PMC supplies the important
growth factors for wound healing and tissue regeneration, which can then be
brought directly in the wound area. The therapeutic goal is to accelerate
and also improve wound healing with cost-efficiency at the same time.
The areas of application for the ATR(R)-curasan set include severe skin
damage such as ulcers, large-area burns, skin transplantations, cartilage
and cell culture or chronic wounds. Furthermore, the growth factors can
have a favourable impact on the wound healing process for the optimised
regeneration of bones and mucous membranes in plastic surgery, in oral and
maxillofacial surgery and implantology.
The ATR(R)-curasan set offers an economically relevant advantage as the
processing does neither require additional devices like centrifuges, nor
the assignment of external laboratories. Therefore, the medical product can
be conveniently employed regardless of the location in practices, hospitals
or in home care without causing any further investment cost or expenses for
services of third parties.
Since the ATR(R)-curasan set is a disposable product and all parts of the
set come in sterile packaging, there is no danger of the PMC being
contaminated. It can even be used in the sterile surgical area.
The cost for treating chronical wounds add up to approximately 4-5 billion
Euros per year in Germany. An estimated 5-8 % of the population is affected
from difficult-to-heal open sores, mostly due to diabetic foot ulcer, leg
ulcer and decubitus. The treatment of a diabetic foot ulcer with growth
factors indicates advantages with regard to a complete wound healing as
well as the duration of the therapy.
An accelerated wound healing allows cost-savings, a faster recovery of the
patient and a reduction of medication, e.g. pain medication, in the further
course of the treatment.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading
companies in the field of regenerative medicine especially in bone and
tissue regeneration. The company has developed a future-oriented product
pipeline in synthetic bone substitutes and bone regeneration material. Some
of these various new developments are ready for market rollout. Further
products are about to follow within the next two years. These biomaterials
will be distributed in different submarkets by well-positioned contractual
partners. www.curasan.com
A picture can be sent upon request.
Contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner(at)curasan.de
www.curasan.de
fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
j.gleisner(at)finanical-relations.de
End of Corporate News
---------------------------------------------------------------------
30.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info(at)curasan.de
Internet: www.curasan.de
ISIN: DE0005494538
WKN: 549453
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
183453 30.08.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.08.2012 - 08:40 Uhr
Sprache: Deutsch
News-ID 178971
Anzahl Zeichen: 6612
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: curasan AG: Patent granted for platelet-mediator concentrate"
steht unter der journalistisch-redaktionellen Verantwortung von
curasan AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
